What the Tysabri FDA Label Says About PML Risk

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Risk Awareness

If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). This page explains what the FDA label says about PML risk, monitoring, and risk factors, building on decades of research into biologic therapies and their rare but serious side effects.

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC virus. The United States Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, the agency's most stringent safety alert, stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical evidence and postmarketing surveillance data. PML is a demyelinating disease that occurs when the JC virus reactivates in immunocompromised individuals and infects oligodendrocytes in the central nervous system. The clinical presentation of PML can be variable, but common symptoms include progressive neurological deficits such as weakness, gait disturbance, cognitive impairment, and visual changes. In a large retrospective cohort study of 456 Italian PML patients observed between 1987 and 2024, researchers described the demographic, clinical, radiological, and laboratory characteristics of the disease, noting that it affects immunocompromised individuals and can lead to severe disability or death (https://pubmed.ncbi.nlm.nih.gov/40922664/). The diagnosis of PML is typically confirmed through a combination of clinical evaluation, magnetic resonance imaging (MRI) showing characteristic white matter lesions, and detection of JC virus DNA in cerebrospinal fluid.

Mechanism of Risk and FDA Warnings

The mechanistic pathway linking Tysabri to PML involves the drug's pharmacological action. Tysabri is a monoclonal antibody that binds to alpha-4 integrin on the surface of immune cells, preventing their migration across the blood-brain barrier into the central nervous system. This reduces inflammation in the brain, which is beneficial for treating multiple sclerosis, but it also impairs immune surveillance against the JC virus. As a result, the virus can reactivate and cause PML in susceptible patients. The FDA has identified three specific risk factors that increase the likelihood of developing PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment. The FDA Adverse Event Reporting System (FAERS) database contains a large number of adverse-event reports associated with Tysabri. The most frequently reported events include fatigue (19,150 reports), multiple sclerosis relapse (16,691 reports), headache (9,626 reports), gait disturbance (9,422 reports), and memory impairment (7,895 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not specifically quantify PML incidence, they highlight the range of neurological and systemic symptoms that patients may experience during treatment. PML itself is a rare but devastating adverse event, and its occurrence can be catastrophic for affected patients.

Legal Considerations for Tysabri-Related PML

From a risk perspective, the adequacy of warnings regarding Tysabri and PML is a critical issue. The boxed warning on the product label clearly states the increased risk of PML and the need for monitoring. Healthcare professionals are instructed to "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and to "withhold TYSABRI immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, Tysabri is only available through a restricted distribution program called the TOUCH Prescribing Program, which is designed to ensure that patients and prescribers are aware of the risks and that appropriate monitoring is conducted. Despite these measures, questions may arise about whether the warnings are sufficient to protect patients, particularly in cases where PML develops despite adherence to monitoring protocols. For patients who develop PML after Tysabri treatment, attorney-related considerations may be relevant. The timeline between exposure to Tysabri and documented harm is an important factor in legal cases. PML can occur at any time during treatment, but the risk increases with longer duration of therapy, especially beyond two years. The presence of anti-JCV antibodies and prior immunosuppressant use further elevate the risk. In legal contexts, the adequacy of informed consent and the clarity of risk communication may be examined. Patients who were not adequately warned about the risk of PML, or whose risk factors were not properly assessed, may have grounds for legal action. An attorney specializing in Tysabri-related PML cases can help affected patients navigate the complexities of medical malpractice or product liability claims.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the connection between Tysabri and PML?

Tysabri (natalizumab) is a biologic therapy that increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The FDA has issued a boxed warning for this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML occurs when the JC virus reactivates in immunocompromised individuals, leading to demyelination and neurological deficits.

What are the risk factors for developing PML while on Tysabri?

The FDA identifies three key risk factors: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be assessed before and during treatment.

Can I file a lawsuit if I developed PML after taking Tysabri?

Patients who developed PML after Tysabri treatment may have legal options if they were not adequately warned about the risks or if their risk factors were not properly evaluated. An attorney specializing in Tysabri-related PML cases can help determine if there are grounds for a medical malpractice or product liability claim.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.